Follistatin 344
Also known as: FS-344
Follistatin 344 is a recombinant form of the naturally-occurring glycoprotein (344-residue splice variant) that inhibits activin and myostatin signaling. Clinical validation exists ONLY through small AAV gene-therapy phase 1/2 trials in Becker muscular dystrophy; recombinant injectable protein sold on the grey market has no clinical evidence. NOT FDA-approved. WADA-prohibited (myostatin inhibitor) and banned in competitive sport.
Pricing for Follistatin 344
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for Follistatin 344
1 third-party test across 1 vendor. Each card links to the full report.
14 citations indexed for Follistatin 344
Study · 2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement.
review · 2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement.
review · 2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes.
review · 2026
Myostatin Research: From Molecular Understanding to Clinical Translation for Musculoskeletal and Metabolic Disorders
Myostatin (Mstn), a well-characterized member of the transforming growth factor-β (TGF-β) superfamily, serves as a key negative regulator of skeletal muscle mass. Its overactivation is closely associated with the pathogenesis of various musculoskeletal and metabolic disorders.
Study · 2025
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement.
Study · 2025
Gel Electrophoretic Detection of Black Market ACE-031
The usage of ACE-031 (Ramatercept), a dimeric fusion protein consisting of a human activin receptor IIB (ACVR2B) fragment linked to an Fc-part of human IgG1, is banned according to chapter S4.3 of the "WADA 2024 List of Prohibited Substances and Methods" due to its potential performance enhancing properties.